S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
NYSE:OGN

Organon & Co. (OGN) Stock Forecast, Price & News

$16.65
-0.71 (-4.09%)
(As of 10:51 AM ET)
Compare
Today's Range
$16.62
$17.25
50-Day Range
$16.59
$23.77
52-Week Range
$16.42
$32.43
Volume
447,210 shs
Average Volume
2.18 million shs
Market Capitalization
$4.26 billion
P/E Ratio
5.64
Dividend Yield
6.73%
Price Target
$28.25

Organon & Co. MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
66.5% Upside
$28.25 Price Target
Short Interest
Healthy
2.84% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.68mentions of Organon & Co. in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.53%
From $4.29 to $4.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

32nd out of 969 stocks

Pharmaceutical Preparations Industry

8th out of 453 stocks


OGN stock logo

About Organon & Co. (NYSE:OGN) Stock

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Price History

OGN Stock News Headlines

Drugs ‘n Diapers: 5 Dividends Up to 5.9%
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Barclays Begins Coverage on Organon & Co. (NYSE:OGN)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Organon & Company hosts conference call for investors
Organon & Co.: A Tough Spot To Be In Right Now
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Company Calendar

Last Earnings
8/08/2023
Ex-Dividend for 9/14 Dividend
8/17/2023
Dividend Payable
9/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.25
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+62.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$917 million
Pretax Margin
14.30%

Debt

Sales & Book Value

Annual Sales
$6.17 billion
Cash Flow
$5.88 per share
Book Value
($3.51) per share

Miscellaneous

Free Float
252,578,000
Market Cap
$4.44 billion
Optionable
Not Optionable
Beta
0.91
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 63)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 56)
    Exec. VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 55)
    Exec. VP & Chief Commercial Officer
    Comp: $1.44M
  • Dr. Sandra Milligan J.D. (Age 59)
    M.D., Exec. VP and Head of R&D
    Comp: $1.6M
  • Mr. Joseph T. Morrissey Jr. (Age 58)
    Exec. VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 47)
    Exec. VP & Chief Information Officer
  • Ms. Jennifer Halchak
    VP of Investor Relations
  • Mr. Kirke Weaver (Age 50)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Mr. Aaron Falcione (Age 52)
    Exec. VP & Chief HR Officer
  • Mr. Vittorio Nisita (Age 55)
    Exec. VP & Head of Global Bus. Services













OGN Stock - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGN, but not buy additional shares or sell existing shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price forecast for 2023?

4 brokerages have issued 12-month price objectives for Organon & Co.'s shares. Their OGN share price forecasts range from $25.00 to $33.00. On average, they predict the company's share price to reach $28.25 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2023?

Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN stock has decreased by 37.8% and is now trading at $17.36.
View the best growth stocks for 2023 here
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) posted its quarterly earnings data on Tuesday, August, 8th. The company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.34. The business earned $1.61 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 12.22% and a negative trailing twelve-month return on equity of 142.40%. The company's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.25 earnings per share.
Read the conference call transcript
.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Tuesday, August 8th. Investors of record on Friday, August 18th will be paid a dividend of $0.28 per share on Thursday, September 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.45%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.45%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 24.51% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.25 billion-$6.45 billion, compared to the consensus revenue estimate of $6.28 billion.

What is Organon & Co.'s stock symbol?

Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN."

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organon & Co.'s stock price today?

One share of OGN stock can currently be purchased for approximately $17.36.

How much money does Organon & Co. make?

Organon & Co. (NYSE:OGN) has a market capitalization of $4.44 billion and generates $6.17 billion in revenue each year. The company earns $917 million in net income (profit) each year or $2.95 on an earnings per share basis.

How many employees does Organon & Co. have?

The company employs 10,000 workers across the globe.

How can I contact Organon & Co.?

Organon & Co.'s mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The official website for the company is www.organon.com. The company can be reached via phone at 551-430-6900 or via email at investor_relations@organon.com.

This page (NYSE:OGN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -